Data presented by Organon at the 16th World Congress on Fertility andSterility in San Francisco, USA, October 3-9, show its gonadotrophin-releasing hormone antagonist, Orgalutran (ganirelix) can remove the need for pre-treatment before in vitro fertilization stimulation.
The drug will reduce the total treatment time to collection of eggs from four weeks to 10 days and reduce exposure to hormone-suppressing drugs to five or six days. It is expected to be available in late 2000.
Women undergoing IVF are usually pre-treated with a GnRH agonist for two weeks before and during follicle-stimulating hormone administration to suppress the hormone cycle. Orgalutran, however, acts by blocking the GnRH receptor, immediately shutting down endogenous hormone activity, abrogating the need for lengthy pre-treatment and decreasing the total dose of FSH drugs required by 300 units per treatment cycle. Orgalutran treatment is given for four or five days with FSH. The reduced length of treatment may also confer less expense, benefiting many patients who have to bear the cost of the treatment.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze